Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs TransMedics Group Inc — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M), while TransMedics Group Inc trades at $87.02 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 202.2× Avalanche Treasury Corporation Class A Common Stock's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AVAT | TMDX | |
|---|---|---|
Market Cap | $15.33M | $3.10B |
Sector | Financials | Technology |
52-Week High | $10.75 | $150.42 |
52-Week Low | $0.30 | $61.99 |
Enterprise Value | $15.33M | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT trades at $0.3426, up 1.75% today, with a bearish technical signal from moving averages and a P/E of 12. The company reported net income of $8.28 million for 2025, but negative operating cash flow of $930,710 raises concerns about liquidity. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed: profitability and low valuation offer potential upside, but cash flow challenges and bearish technicals present risks. Investor sentiment is cautious due to operational losses, though the public listing may attract institutional interest.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
